TODAY'S PAPER
76° Good Evening
76° Good Evening
ClassifiedsCars

Latest recalls: Cadillacs, bassinets

WASHINGTON - General Motors said Wednesday it is recalling more than 50,000 Cadillac CTS vehicles worldwide, and an Iowa company is recalling about 500,000 bassinets that could collapse if not assembled properly.

GM said its issue is a loose joint that could cause a rear wheel to become unstable, making it difficult for drivers to steer.

The recall affects more than 44,000 CTS vehicles, Cadillac's best-selling model, in the United States from the 2009 and 2010 model years. The remaining vehicles were sold in China and around the globe.

The automaker said there have been no injuries or fatalities related to the recall. Owners can contact Cadillac at 866-982-2339 for more information.

The recalled bassinets were made by Iowa-based Burlington Basket Co. before June 2010. The Consumer Product Safety Commission says the bassinets can collapse if the support rails that hold the basket are not fully locked into place. The CPSC and Burlington Basket have received 10 reports of incidents in which the bassinets collapsed when the folding legs were not locked properly. Two infants had minor injuries. Consumers can contact the company at 800-553-2300 for repair kits and more information.

In other recalls:

The CPSC recalled about 1,200 children's "light-up" watches imported by Walt Disney Parks and Resorts of Lake Buena Vista, Fla., because the watch battery current can interact with nickel in the watch's stainless steel back, causing skin irritations or burning sensations to children who are allergic to nickel. The recall involves Buzz Lightyear, Tinker Bell and Lightning McQueen brand light-up watches. Consumers can contact Walt Disney Parks and Resorts at 877-560-6477 for instructions on returning the watch for a refund.

Johnson & Johnson alerted pharmacists and health care providers it has recalled 70,000 syringes filled with the antipsychotic drug Invega because of cracks in the syringes, which possibly could affect the drug's sterility. A company spokesman said the issue, discovered during routine testing, has been resolved and production of the syringes has resumed at its manufacturing facility in Belgium.

Combined News Services

Comments

We're revamping our Comments section. Learn more and share your input.

More news